Adjusts engineered cyclic peptides rules for Drug Price Negotiation Program under Social Security Act.

The Next Generation Medicines Act of 2026 amends the Social Security Act to redefine engineered cyclic peptides for the Drug Price Negotiation Program. It specifies these peptides must be composed of amino acids, contain at least one cyclic structure, have up to 40 amino acids, be identified through a genetically encoded library screening method, not be naturally derived, and be self-administered. The bill also extends the qualifying period for these peptides from 7 to 11 years. These changes apply to lists published under the Drug Price Negotiation Program after the enactment of this Act.

Adjusts engineered cyclic peptides rules for Drug Price Negotiation Program under Social Security Act.

The Next Generation Medicines Act of 2026 amends the Social Security Act to redefine engineered cyclic peptides for the Drug Price Negotiation Program. It specifies these peptides must be composed of amino acids, contain at least one cyclic structure, have up to 40 amino acids, be identified through a genetically encoded library screening method, not be naturally derived, and be self-administered. The bill also extends the qualifying period for these peptides from 7 to 11 years. These changes apply to lists published under the Drug Price Negotiation Program after the enactment of this Act.